Pharmacokinetics of terbinafine

Reviews in Contemporary Pharmacotherapy

Volumn 8, Issue 5, 1997, Pages 289-297

  Faergemann, Jan ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE; ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

CONTROLLED STUDY; DERMATOMYCOSIS; DERMATOPHYTE; DERMIS; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TISSUE LEVEL; EPIDERMIS; FUNGICIDAL ACTIVITY; HAIR; HUMAN; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; NAIL; REVIEW; SEBUM; STRATUM CORNEUM;

EID: 0030706205     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Cauwenbergh G, Degreef H, Heykants J, Woestenborghe R, van Rooy P, Haeverane K. Pharmacokinetc profile of orally administered itraconazole. J Am Acad Dermatol 1988; 18: 263-268.
2. Dykes PJ, Thomas R, Finlay AY. Determination of terbinafine in nail samples during systemic treatment for onychomycosis. Br J Dermatol 1990; 123: 481-486.
3. Epstein WL, Shah WOP, Riegelman S. Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch Dermatol 1972; 106: 334-348.
4. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993; 18: 102-106.
5. Faergemann J, Laufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once daily. Acta Derm Venereol (Stockh) 1996; 76: 219-221.
6. Faergemann, J, Zehender H, Jones T, Maibach HL. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol (Stockh) 1990; 70: 322-326.
7. Faergemann J, Zehender H, Denouël J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol (Stockh) 1993; 73: 305-309.
8. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-126.
9. Faergemann J, Zehender H, Boukhabza A, Ganslandt J, Jones TC. Comparison of terbinafine levels in stratum corneum and dermis-epidermis (without stratum corneum) after topical or topical combined with oral therapy in healthy volunteers. J Eur Acad Dermatol Venereol 1995; 5 (Suppl 1): S94.
10. Faergemann J, Zehender H, Boukhabza A, Smith SG, Jones TC. A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication. Acta Derm Venereol (Stockh) 1997; 77: 74-76.
11. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992a; 126 (Suppl 39): 28-32.
12. Finlay AY. Pharmacokinetics of terbinafine in the nail. J Dermatol Treat 1992b; 3 (Suppl 1): 15-17.
13. Finlay AY, Lever L, Thomas R, Dykes PJ. Nail matrix of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1 (Suppl 2): 51-53.
14. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. Br J Dermatol 1992; 126 (Suppl 39): 33-35.
15. Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to the stratum corneum. Antimicrob Agents Chemother 1983; 24: 876-882.
16. Jensen JC. Clinical pharmacokinetics of terbinafine. Clin Exp Dermatol 1989; 14: 110-114.
17. Kovarik JM, Kirkesseli S, Humbert H, Grass P, Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992; 126 (Suppl 39): 8-13.
18. Kovarik JM, Mueller EA, Zehender H, Denouël J, Caplain H, Milleroux L. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995; 39: 2738-2741.
19. Lever LR, Dykes PJ, Thomas R, Finlay AY. How orally administered terbinafine reaches the stratum corneum. J Dermatol Treat 1990; 1 (Suppl 2): 23-25.
20. Marks R, Dawber RPR. Skin surface biopsy: an improved technique for the examination of the horny layer. Br J Dermatol 1971; 84: 117-123.
21. Matthieu L, De Doncker P, Cauwenbergh G et al. Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374-376.
22. Munro C, Rees J, Shuster S. Short duration terbinafine therapy penetrates diseased distal nails via the ventral nail bed and is effective in onychomycosis. Br J Dermatol 1990; 123: 825.
23. Petranyi G, Ryder NS, Stütz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239-1242.
24. Schatz F, Bräutigam M, Dobrowolski E et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-383.
25. White JE, Perkins PJ, Evans EGV. Successful 2 week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manum. Br J Dermatol 1991; 125: 260-262.
26. Willemsen M, De Doncker P, Willems J et al. Posttreatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26: 731-735.
27. Zehender H, Cabiac MD, Denouël J et al. Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites. Drug Invest 1994; 8: 203-210.